标题:Silodosin is effective for treatment of LUTS in men with BPH: a systematic review
作者:Ding, Hui; Du, Wan; Hou, Zi-Zhen; Wang, Han-Zhang; Wang, Zhi-Ping
作者机构:[Ding Hui] Institute of Urology, Gansu Nephro-UrologicaI Clinical Center, The Second Hospital of Lanzhou University, Key Laboratory of Diseases of Uro 更多
通讯作者:Wang, ZP(erywzp@lzu.edu.cn)
通讯作者地址:[Wang, ZP]Lanzhou Univ, Hosp 2, Key Lab Dis Urol Syst Gansu Prov, Gansu Nephrourol Clin Ctr,Inst Urol, Lanzhou 730000, Peoples R China.
来源:ASIAN JOURNAL OF ANDROLOGY
出版年:2013
卷:15
期:1
页码:121-128
DOI:10.1038/aja.2012.102
关键词:benign prostatic hyperplasia (BPH); KMD-3213; lower urinary tract; symptoms (LUTS); silodosin; tamsulosin; systematic review; meta-analysis
摘要:The aim of this study was to systematically review the evidence on the efficacy and safety of silodosin treatments on lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) from randomized controlled trials. We searched PubMed (1966-December 2011), Embase (1974-December 2011) and the Cochrane Library Database (2011, Issue 12). The assessed outcome measures were the change from baseline for the International Prostate Symptom Score (IPSS), quality of life (QoL) score, peak urine maximum flow rate (Q(max)), QoL related to urinary symptoms and adverse effects. Two authors independently assessed the study quality and extracted data. All data were analysed using RevMan 5.1. The meta-analysis included four randomized controlled trials with a total of 2504 patients. The study durations were each 12 weeks. At the follow-up end points, the pooled results showed that the change from baseline for the silodosin group was significantly higher than the placebo group for the IPSS, QoL score and Q(max)(mean difference (MD)=-22.78, P<0.00001; MD=-0.42, P=0.004; MD=1.17, P<0.00001, respectively) and patients felt more satisfied with QoL related to urinary symptoms in the silodosin group than the placebo group. Ejaculation disorder was the most commonly reported adverse effect. The pooled results also showed that the silodosin group was superior to the 0.2 mg tamsulosin group with respect to the IPSS and QoL score (IPSS: MD=-1.14, P=0.02; QoL score: MD=-0.26, P=0.02) and inferior to the 0.2 mg tamsulosin group with respect to Q(max) (MD=-0.85, P=0.01). In contrast, there was no significant difference in the incidence of ejaculation disorder and dizziness between the silodosin and 0.2 mg tamsulosin groups. The current meta-analysis suggested that silodosin is an effective therapy for LUTS in men with BPH and is not inferior to 0.2 mg tamsulosin. Asian Journal of Andrology (2013) 15, 121-128; doi:10.1038/aja.2012.102; published online 10 December 2012
收录类别:CSCD;SCOPUS;SCIE
WOS核心被引频次:13
Scopus被引频次:14
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872194968&doi=10.1038%2faja.2012.102&partnerID=40&md5=c7fe4bf095af9fc316b0e8fe86658b05
TOP